Compile Data Set for Download or QSAR
Report error Found 129 Enz. Inhib. hit(s) with all data for entry = 10483
TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539937(4-(((3S,4S)-1- ((2,4- dichlorophenyl) sulfonyl)-4-...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539872(4-(((3S,4R)-1- ((2-chloro-4- cyanophenyl)sulfonyl)...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539936(4-(((3R,4S)-4-((4-bromophenyl)sulfonyl)-3-hydroxy-...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539875(4-(((3S,4R)-1- ((2-chloro-4- methylphenyl)sulfonyl...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539874(4-(((3S,4R)-1- ((2-chloro-4- fluorophenyl)sulfonyl...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539876(2-chloro-4-(difluoro- methyl)benzene-1- sulfonyl c...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539879(5-chloro-2- (((3R,4S)-4-((4- chlorophenyl)sulfonyl...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539878(4-chloro-2- methoxybenzene- 1-sulfonyl chloride | ...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539881(4-(((3R,4S)-4- ((4-chloro- phenyl)sulfonyl)- 3-hyd...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521185(CHEMBL4439448 | US11260049, Ex. 83)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50505546(CHEMBL4533534 | US11260049, Ex. 82)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521195(CHEMBL4586959 | US11260049, Ex. 84)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539949(4-(((3S,4R)-1- ((2,4- dichlorophenyl) sulfonyl)-4-...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539887(4-(((3S,4R)-1- ((4-chloro-2- (trifluoromethyl) phe...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539950((3R,4S)-4-((4- chloro-3- fluorophenyl) sulfonyl)-1...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539921(4-(((3S,4R)-1- ((2-bromo-4- chlorophenyl)sulfonyl)...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521182(CHEMBL4456312 | US11260049, Ex. 123)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539984(4-(((3R,4S)-3- (aminomethyl)-4- ((4-chlorophenyl) ...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521183(CHEMBL4461475 | US11260049, Ex. 125)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539986(3-chloro-4- (((3S,4S)-4-((4- chlorophenyl) sulfony...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521180(CHEMBL4437115 | US11260049, Ex. 1)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539865(4-(((3S,4S)-1- ((2-chloro-4- cyanophenyl)sulfonyl)...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50505550(CHEMBL4439190 | US11260049, Ex. 2)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539932(4-(((3S,4R)-1- ((4-cyano-2-methyl- phenyl)sulfonyl...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539969(3-chloro-4- (((3R,4S)-4-((4- chloro-3- fluoropheny...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521186(CHEMBL4547101 | US11260049, Ex. 45)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539975(4-(((3R,4S)-4-((5- bromopyridin-2- yl)sulfonyl)-3-...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539910(4-(((3R,4S)-4- ((4-chloro- phenyl)sulfonyl)- 3-hyd...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539979(2-(((3R,4S)-4-((4- chlorophenyl) sulfonyl)-3- hydr...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539917(3- (difluoromethyl)- 4-(((3R,4S)-3- hydroxy-3- (hy...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539981(3-chloro-4-(((3R,4S)-4-((5-chloropyridin-2-yl)sulf...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539916(3-chloro-4- (((3R,4S)-3- hydroxy-3- (hydroxymethyl...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM50521192(CHEMBL4547537 | US11260049, Ex. 121)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539982(3-chloro-4-(((3R,4S)-4-((5-chloropyridin-2-yl)sulf...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539891(4-(((3S,4R)-1- ((4-fluoro-2- (trifluoromethyl) phe...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539892(4-(((3S,4R)-1- ((4-bromo-2- (trifluoromethyl) phen...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539897(4-(((3R,4S)-4- ((4-chloro- phenyl)sulfonyl)- 3-hyd...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539896(4-(((3S,4R)-1- ((4-bromo-2- chlorophenyl)sulfonyl)...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539900(3-bromo-4- (((3R,4S)-4-((4- chlorophenyl)sulfonyl)...)
Affinity DataIC50: 5nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539873(4-(((3S,4R)-1- ((2-chloro- phenyl)sulfonyl)- 4-hyd...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539877(2-(difluoro- methoxy)pyridine- 3-sulfonyl chloride...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539880(4-cyano-2- (trifluoro- methyl)benzene-1- sulfonyl ...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539883(4-(((3R,4S)-4- ((4-chloro- phenyl)sulfonyl)- 3-hyd...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539882(4-cyano-2- ethoxybenzene-1- sulfonyl chloride | US...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539885(3-chloro-4- (((3S,4S)-4-((4- chlorophenyl)sulfonyl...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539876(2-chloro-4-(difluoro- methyl)benzene-1- sulfonyl c...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539886(4-(((3S,4S)-4- ((4-bromo- phenyl)sulfonyl)- 3-hydr...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539989(4-(((3R,4S)-3- (aminomethyl)-4- ((4-chlorophenyl) ...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539988(4-(((3S,4S)-3- (aminomethyl)-4- ((4-chlorophenyl) ...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

TargetTransient receptor potential cation channel subfamily V member 4(Human)
Glaxosmithkline Intellectual Property (No. 2)

US Patent
LigandPNGBDBM539991(3-chloro-4-(((4S,5R)-4-((5-chloropyridin-2-yl)sulf...)
Affinity DataIC50: 55nMAssay Description:TRPV4 channel activation results in an influx of divalent and monovalent cations including calcium. The resulting changes in intracellular calcium we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/24/2022
Entry Details
US Patent

Displayed 1 to 50 (of 129 total ) | Next | Last >>
Jump to: